Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation
暂无分享,去创建一个
Ruben Abagyan | Irina Kufareva | Tracy M Handel | Ling Qin | Tetsuya Kawamura | Chunxia Zhao | Bryan S Stephens | Lauren G Holden
[1] T. Hara,et al. CXCL14 is a natural inhibitor of the CXCL12–CXCR4 signaling axis , 2013, FEBS letters.
[2] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[3] J. Wess,et al. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[5] Adam J Kuszak,et al. Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. , 2009, The Journal of biological chemistry.
[6] Dan Li,et al. Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches. , 2013, Molecular bioSystems.
[7] Michel Bouvier,et al. Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers* , 2005, Journal of Biological Chemistry.
[8] B. Sykes,et al. Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.
[9] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[10] T. Jin,et al. Fluorescence Resonance Energy Transfer Imaging Reveals that Chemokine-Binding Modulates Heterodimers of CXCR4 and CCR5 Receptors , 2008, PloS one.
[11] J. Qian,et al. Visualization of arrestin recruitment by a G Protein-Coupled Receptor , 2014, Nature.
[12] Dominique Schols,et al. Mutations at the CXCR4 interaction sites for AMD3100 influence anti‐CXCR4 antibody binding and HIV‐1 entry , 2003, FEBS letters.
[13] M. Parmentier,et al. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of “Selective” Antagonists* , 2009, The Journal of Biological Chemistry.
[14] Leigh A. Stoddart,et al. Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] G. Milligan. The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization , 2013, Molecular Pharmacology.
[16] N. Heveker,et al. Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.
[17] Dominique Schols,et al. Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor* , 2007, Journal of Biological Chemistry.
[18] Won-Tak Choi,et al. Unique Ligand Binding Sites on CXCR4 Probed by a Chemical Biology Approach: Implications for the Design of Selective Human Immunodeficiency Virus Type 1 Inhibitors , 2005, Journal of Virology.
[19] Pierre Corvol,et al. Polar Residues in the Transmembrane Domains of the Type 1 Angiotensin II Receptor Are Required for Binding and Coupling , 1996, The Journal of Biological Chemistry.
[20] T. Handel,et al. Chemokine receptor oligomerization and allostery. , 2013, Progress in molecular biology and translational science.
[21] Cristina Limatola,et al. Ligand-independent CXCR2 Dimerization* , 2003, Journal of Biological Chemistry.
[22] R. Wong,et al. Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors , 2008, Molecular Pharmacology.
[23] Garland R Marshall,et al. Insight into the Binding Mode for Cyclopentapeptide Antagonists of the CXCR4 Receptor , 2006, Chemical biology & drug design.
[24] T. Sakmar,et al. CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration* , 2011, The Journal of Biological Chemistry.
[25] R. Gorlin,et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.
[26] Mudit Gupta,et al. Imaging chemokine receptor dimerization with firefly luciferase complementation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] M. Simon,et al. G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. , 1995, The Journal of biological chemistry.
[28] N. Heveker,et al. AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties , 2009, Molecular Pharmacology.
[29] T. Schall,et al. Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands , 2009, The Journal of Immunology.
[30] Masahiko Kuroda,et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.
[31] Ruben Abagyan,et al. Compound activity prediction using models of binding pockets or ligand properties in 3D. , 2012, Current topics in medicinal chemistry.
[32] Hideo Takahashi,et al. Structural Basis of the Interaction between Chemokine Stromal Cell-derived Factor-1/CXCL12 and Its G-protein-coupled Receptor CXCR4* , 2009, The Journal of Biological Chemistry.
[33] Graeme Milligan,et al. Domain Swapping in the Human Histamine H1 Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.
[34] J. Pin,et al. Activation of a Dimeric Metabotropic Glutamate Receptor by Intersubunit Rearrangement* , 2007, Journal of Biological Chemistry.
[35] Albert Zlotnik,et al. Homeostatic chemokine receptors and organ-specific metastasis , 2011, Nature Reviews Immunology.
[36] R. Abagyan,et al. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.
[37] Gregory J Babcock,et al. Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.
[38] Richard N. Zare,et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein , 2007, Proceedings of the National Academy of Sciences.
[39] F. Baleux,et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. , 2009, Blood.
[40] Tullio Pozzan,et al. CXCR4–CCR5: A couple modulating T cell functions , 2008, Proceedings of the National Academy of Sciences.
[41] N. Heveker,et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways , 2011, Proceedings of the National Academy of Sciences.
[42] R. Abagyan,et al. A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer. , 2013, Methods in molecular biology.
[43] E. De Clercq,et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.
[44] T. Schall,et al. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells , 2011, Molecular Cancer.
[45] T. Handel,et al. Modulation of chemokine receptor activity through dimerization and crosstalk , 2009, Cellular and Molecular Life Sciences.
[46] R. Bronson,et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[47] H. Tai,et al. Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding. , 2000, Archives of biochemistry and biophysics.
[48] F. Baleux,et al. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. , 2008, Blood.
[49] S. Sligar,et al. Monomeric Rhodopsin Is Sufficient for Normal Rhodopsin Kinase (GRK1) Phosphorylation and Arrestin-1 Binding* , 2010, The Journal of Biological Chemistry.
[50] Marc Parmentier,et al. Allosteric Transinhibition by Specific Antagonists in CCR2/CXCR4 Heterodimers* , 2007, Journal of Biological Chemistry.
[51] W. Fischer,et al. In Silico Analysis Reveals Sequential Interactions and Protein Conformational Changes during the Binding of Chemokine CXCL-8 to Its Receptor CXCR1 , 2014, PloS one.
[52] N. V. van Nuland,et al. Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. , 2012, Biochemical pharmacology.
[53] B. Sykes,et al. Neutrophil activation by monomeric interleukin-8. , 1994, Science.
[54] M. Simon,et al. Gα15 and Gα16 Couple a Wide Variety of Receptors to Phospholipase C (*) , 1995, The Journal of Biological Chemistry.
[55] A. Marchese,et al. CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin* , 2010, The Journal of Biological Chemistry.
[56] Mario Mellado,et al. Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways , 2001, The EMBO journal.
[57] Kuan-Teh Jeang,et al. Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.
[58] Christoph Seibert,et al. Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.
[59] L. Hunyady,et al. Allosteric interactions within the AT₁ angiotensin receptor homodimer: role of the conserved DRY motif. , 2012, Biochemical pharmacology.
[60] Krzysztof Palczewski,et al. Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.
[61] R. Leurs,et al. Pharmacological modulation of chemokine receptor function , 2012, British journal of pharmacology.
[62] R. Ghirlando,et al. Modulation of the interaction between neurotensin receptor NTS1 and Gq protein by lipid. , 2012, Journal of molecular biology.
[63] M. Farzan,et al. The Role of Post-translational Modifications of the CXCR4 Amino Terminus in Stromal-derived Factor 1α Association and HIV-1 Entry* , 2002, The Journal of Biological Chemistry.
[64] R. Abagyan,et al. Soft protein–protein docking in internal coordinates , 2002, Protein science : a publication of the Protein Society.
[65] R. Koenen,et al. Heterophilic chemokine receptor interactions in chemokine signaling and biology. , 2011, Experimental cell research.
[66] Nafis Rahman,et al. Rescue of defective G protein–coupled receptor function in vivo by intermolecular cooperation , 2010, Proceedings of the National Academy of Sciences.
[67] J. Trejo,et al. Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling* , 2013, The Journal of Biological Chemistry.
[68] P. Toth,et al. Regulation of CXCR4 Receptor Dimerization by the Chemokine SDF-1α and the HIV-1 Coat Protein gp120: A Fluorescence Resonance Energy Transfer (FRET) Study , 2004, Journal of Pharmacology and Experimental Therapeutics.
[69] Ruben Abagyan,et al. Role of 3D Structures in Understanding, Predicting, and Designing Molecular Interactions in the Chemokine Receptor Family , 2014 .
[70] B. Volkman,et al. The CXC Chemokine Receptor 4 Ligands Ubiquitin and Stromal Cell-derived Factor-1α Function through Distinct Receptor Interactions* , 2011, The Journal of Biological Chemistry.
[71] Krzysztof Palczewski,et al. Efficient Coupling of Transducin to Monomeric Rhodopsin in a Phospholipid Bilayer* , 2008, Journal of Biological Chemistry.
[72] Andrea Iaboni,et al. A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.
[73] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[74] N. Aiyar,et al. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. , 2001, Immunology letters.
[75] Allen P. Liu,et al. Multiplex Detection of Homo- and Heterodimerization of G Protein-Coupled Receptors by Proximity Biotinylation , 2014, PloS one.
[76] D. Sinnett,et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. , 2010, The Journal of biological chemistry.
[77] Maxim Totrov,et al. Atomic Property Fields: Generalized 3D Pharmacophoric Potential for Automated Ligand Superposition, Pharmacophore Elucidation and 3D QSAR , 2007, Chemical biology & drug design.
[78] Hualiang Jiang,et al. Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.
[79] Won-Tak Choi,et al. Distinct Functional Sites for Human Immunodeficiency Virus Type 1 and Stromal Cell-Derived Factor 1α on CXCR4 Transmembrane Helical Domains , 2005, Journal of Virology.
[80] F. Hamdan,et al. Monitoring Protein‐Protein Interactions in Living Cells by Bioluminescence Resonance Energy Transfer (BRET) , 2006, Current protocols in neuroscience.
[81] J. Sodroski,et al. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. , 2012, Biochemistry.
[82] T. Handel,et al. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery. , 2013, ACS chemical biology.
[83] Zhaowen Luo,et al. Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* , 2001, The Journal of Biological Chemistry.
[84] T. Schwartz,et al. Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor* , 2001, The Journal of Biological Chemistry.
[85] M. Parmentier,et al. Evidence for Negative Binding Cooperativity within CCR5-CCR2b Heterodimers , 2005, Molecular Pharmacology.